Category: Disclosures

[Disclosure] Hanwha Aerospace (012450) – Decision on Cash Dividends / 2025-02-24

February 24, 2025August 10, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Aerospace has disclosed a decision to pay a year-end cash dividend of KRW 3,500 per common share, totaling approximately KRW 159.1B for FY2024. 📊 [Key Disclosure Contents & Major Financial Figures] 1. Dividend Details & Key Figures 2. Record Date and AGM Schedule 3. Other…

Disclosures, Defense

[Disclosure] Jeju Semiconductor (080220) – (Correction) Decision on Issuance of Convertible Bonds (8th Series) / 2025-02-24

February 24, 2025August 3, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Jeju Semiconductor has submitted a corrected disclosure changing the issuance format of its 8th series private convertible bonds (CB) from electronic registration to physical issuance and postponing the payment date and maturity date by two days. 📊 [Key Disclosure Contents & Summary of Major Figures] 📝…

Semiconductors, Disclosures

[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Application for CT-P13 SC (Remsima Subcutaneous) in Pediatric Ulcerative Colitis in Korea / 2025-02-24

February 24, 2025August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received approval from the Ministry of Food and Drug Safety (MFDS) of South Korea for its Phase 3 Clinical Trial Application (IND) of CT-P13 SC (Remsima Subcutaneous) in pediatric patients with moderately to severely active ulcerative colitis. 📊 Key Disclosure Content & Financial Highlights 📝…

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – Approval of European Commission Marketing Authorization for Avtozma (CT-P47, Actemra/RoActemra Biosimilar) / 2025-02-24

February 24, 2025August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received final marketing authorization from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Actemra/RoActemra, covering all reference indications across 30 European countries. 📊 Key Disclosure Content & Financial Highlights 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of EC Marketing Authorization Listing in…

Disclosures, Bio & Healthcare

[Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Application for CT-P13 SC (Remsima Subcutaneous) in Pediatric Crohn’s Disease in Korea / 2025-02-24

February 24, 2025August 6, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion received approval from the Ministry of Food and Drug Safety (MFDS) of South Korea for its Phase 3 Clinical Trial Application (IND) of CT-P13 SC (Remsima Subcutaneous) in pediatric patients with moderately to severely active Crohn’s disease. 📊 Key Disclosure Content & Financial Highlights 📝…

Disclosures, Bio & Healthcare

[Disclosure] Samsung Electro-Mechanics (009150) – Submission of Audit Report / 2025-02-21

February 21, 2025July 30, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Electro-Mechanics submitted its Audit Report for FY2024, receiving an ‘Unqualified’ audit opinion from Deloitte Anjin LLC. Consolidated sales revenue for FY2024 reached approximately KRW 10.29T, with operating profit of KRW 735.0B. 📊 [Summary of Key Disclosure Facts & Figures] 1. Audit Opinion & Auditor Details…

Semiconductors, Disclosures

[Disclosure] Hanwha Systems (272210) – Decision on Cash and In-Kind Dividend / 2025-02-21

February 21, 2025August 11, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Systems has resolved to pay a year-end cash dividend of KRW 350 per common share for FY2024, totaling approximately KRW 65.45B. The dividend yield is 1.60%. 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Monitoring AGM Approval and Dividend…

Disclosures, Defense

[Disclosure] Hanwha Systems (272210) – (Correction) Change in Revenue or Operating Profit/Loss by 30% or More / 2025-02-21

February 21, 2025August 11, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Systems has amended its FY2024 financial results previously reported on February 7, 2025. Following the internal settlement adjustments, net profit was revised upward by approximately KRW 133M to KRW 445.38B (+29.8% YoY). 📊 [Key Disclosure Details & Financial Highlights] 📝 Editor’s Comment (Key Follow-up Checkpoint)…

Disclosures, Defense

[Disclosure] Hanwha Systems (272210) – Decision on Convocation of General Meeting of Shareholders / 2025-02-21

February 21, 2025August 11, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Hanwha Systems will hold its 25th Annual General Meeting of Shareholders on March 24, 2025, at 09:00 KST. Major agenda items include approval of financial statements with a cash dividend of KRW 350 per share, amendments to the articles of incorporation, and re-appointment of directors and…

Disclosures, Defense

[Disclosure] ISU PETASYS (007660) – Decision on Paid-in Capital Increase / 2025-02-21

February 21, 2025August 1, 2026 K-STOCK Editor

Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ISU PETASYS revised its rights offering filing as the 1st issue price was finalized at KRW 33,500 per share, increasing the expected facility fund procurement amount to approximately KRW 340.5 billion. 📊 [Key Disclosure Details & Financial Figures] Key Offering Terms & Capital Breakdown: 📝 Editor’s…

Semiconductors, Disclosures